Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 3Phase 1 3Phase 2/3 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Thoracic 1Sarcoma 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 91Melanoma 74Squamous Cell Carcinoma of Head and Neck 47Neoplasms 44Neoplasm Metastasis 43Lung Neoplasms 37Carcinoma, Renal Cell 36Colorectal Neoplasms 35Breast Neoplasms 34Triple Negative Breast Neoplasms 30Stomach Neoplasms 26Carcinoma, Transitional Cell 26Ovarian Neoplasms 25Head and Neck Neoplasms 24Parkinson Disease 4, Autosomal Dominant Lewy Body 21Esophageal Neoplasms 20Pancreatic Neoplasms 18Uterine Cervical Neoplasms 17Urinary Bladder Neoplasms 16Endometrial Neoplasms 16Small Cell Lung Carcinoma 15Carcinoma, Hepatocellular 15Sarcoma 13Recurrence 12Glioblastoma 12Carcinoma 12Prostatic Neoplasms 11Lymphoma 11Mesothelioma 9Carcinoma, Merkel Cell 9

Interventions

Ipilimumab 5Nivolumab 4pembrolizumab 3sargramostim 2fludarabine 2binimetinib 2aldesleukin 2Interleukin-2 2Granulocyte-Macrophage Colony-Stimulating Factor 2Cyclophosphamide 2trametinib 1tebentafusp 1sotrastaurin 1montanide ISA 51 1incomplete Freund's adjuvant 1glembatumumab vedotin 1fludarabine phosphate 1entrectinib 1Valproic Acid 1Tramadol 1Thalidomide 1Temozolomide 1Solutions 1Ruthenium-106 1Radiotherapy 1RNA, Messenger 1Protein Kinase C 1Melphalan 1Magnetic Resonance Spectroscopy 1Ibuprofen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Uveal Melanoma × pembrolizumab × Clear all
NCT04130516 2025-12-18

Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab

Linnaeus Therapeutics, Inc.

Phase 1/2 Recruiting
200 enrolled
DermatologicGastrointestinalThoracic

Uveal Melanoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

NCT06784648 2025-11-19

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

BioInvent International AB

Phase 1/2 Active not recruiting
35 enrolled
Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT03611868 2025-08-07

A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Ascentage Pharma Group Inc.

Phase 1/2 Active not recruiting
230 enrolled
DermatologicSarcoma

Uveal Melanoma, Melanoma, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡